RxDoctor Payments Data

Cara Riley, DO

Internal Medicine · Bella Vista, ARNPI 1578536017

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.9% of the total across 410 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 9.5% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,220in general payments, 2019–2025

Across 410 payments — averaging $15.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$590
  • Amgen$566
  • GSK$541
  • Pfizer$505
  • Novo Nordisk$504
  • Abbott$503
  • plus $3K from 29 others

What the payments were for

  • Food & beverage$6,214100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,220 in reported general payments places this provider in the 90th percentile of 614 internal medicine providers in Arkansas.

See all internal medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$310,955
Medicare patients
534
Services billed
6,618

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide151$218,930
MounjaroTirzepatide149$207,286
EliquisApixaban161$146,807
Trelegy ElliptaFluticasone/Umeclidin/Vilanter104$79,103
JardianceEmpagliflozin60$72,628
XareltoRivaroxaban77$61,848
RybelsusSemaglutide45$55,872
TrulicityDulaglutide26$53,630
JanuviaSitagliptin Phosphate41$42,440
ProliaDenosumab20$34,961
Soliqua 100-33Insulin Glargine/Lixisenatide28$26,894
LinzessLinaclotide31$26,720
MyrbetriqMirabegron36$25,303
FarxigaDapagliflozin Propanediol17$22,793
EntrestoSacubitril/Valsartan15$20,605

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$504$274,802196 claims
Lilly USA, LLCMounjaro, Trulicity$420$260,916175 claims
PfizerEliquis, Premarin$505$154,424174 claims
GSKTrelegy Ellipta, Anoro Ellipta$541$93,986129 claims
Boehringer IngelheimJardiance$157$72,62860 claims
Johnson & JohnsonXarelto$237$61,84877 claims
AstraZenecaFarxiga, Breztri Aerosphere, Nexium, Bevespi Aerosphere$326$47,52058 claims
MerckJanuvia$74$42,44041 claims
AmgenProlia$566$34,96120 claims
AbbVieLinzess, Synthroid$590$30,98384 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$34$26,89428 claims
Astellas Pharma US IncMyrbetriq$328$25,30336 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 614 internal medicine providers in Arkansas.

Other internal medicine in Bella Vista

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →